Status:
COMPLETED
A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Lead Sponsor:
Pfizer
Conditions:
Transthyretin Amyloid Cardiomyopathy
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to learn about the safety of Tafamidis for the treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM) in India. ATTR-CM is a condition that affects people's hearts. ...
Eligibility Criteria
Inclusion
- Adult patients (age ≥18 years) with diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
- Patients to whom VyndaMx® Capsules is prescribed for the treatment of wild or hereditary ATTR-CM.
Exclusion
- Patient with hypersensitivity to VyndaMx® Capsule or to any of the excipients in the product.
- Patients with rare hereditary problems of fructose intolerance.
- Patient who has a contraindication to VyndaMx® Capsules according to the approved local product label.
Key Trial Info
Start Date :
March 25 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 6 2025
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06086353
Start Date
March 25 2024
End Date
June 6 2025
Last Update
November 20 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Sri Jayadeva Institute of Cardiovascular Sciences and Research
Bangalore, Karnataka, India, 560069
2
AIG Hospital
Hyderabad, India, 500032
3
Max Super Speciality Hospital
New Delhi, India, 110017